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491.doi:10.1016/j.jtcvs.2004.08.045Objectives: Thrombotic events have been reported as a major cause of morbidity
after the Fontan procedure. There is no consensus concerning the postoperative
mode and duration of anticoagulation prophylaxis. In a retrospective study, we
evaluated the results of a prophylactic regimen on the basis of the surgical tech-
nique, potentially predisposing risk factors, and specific sequelae.
Methods: We evaluated 142 surviving patients after total cavopulmonary anasto-
mosis (mean follow-up was 91.1  43.9 months). Prophylactic antithrombotic
treatment was initiated in 86 patients with partial prosthetic venous pathway with
acetylsalicylic acid; 45 patients with complete autologous tissue venous pathway or
partial prosthetic venous pathway received no anticoagulation, and 11 patients
received warfarin sodium (Coumadin). During long-term follow-up, 22 patients (12
after acetylsalicylic acid medication) crossed over to warfarin.
Results: Thrombotic events occurred in 10 patients (7%), with systemic venous
thrombus formation in 8 (5.6%), stroke in 2 (1.4%), and a peak incidence during the
first postoperative year. Eight of 10 patients were receiving heparin therapy mainly
for prolonged postoperative immobilization. During follow-up, none of the 74
patients receiving acetylsalicylic acid and 1 of 40 patients without medication
presented with thrombus formation. Under warfarin medication, 1 of 28 patients had
an asymptomatic thrombus. Expected freedom from a thromboembolic event was
92% at 5 years and 79% at 10 years. There was no association with coagulation
factor abnormalities. Protein-losing enteropathy was present in 4 of 10 patients.
Conclusion: A prophylactic anticoagulation strategy that considers the surgical
technique and potential predisposing circumstances proved effective in the preven-
tion of late thrombotic complications after total cavopulmonary anastomosis. There
is no need for routine anticoagulation during long-term follow-up after Fontan-type
surgery in pediatric patients.
Late morbidity and long-term prognosis after the Fontan operation aremainly determined by atrial dysrhythmia, systemic ventricular dys-function, protein-losing enteropathy, hepatic dysfunction, andthromboembolic complications.1-3 Few data are available that ana-lyze the time course of thromboembolism and that demonstrate apersistent implied risk throughout the time of follow-up.4 Systemic
venous thromboembolic complications have been described in 3% to 20%.4-6 The
incidence of arterial thromboembolic events ranged from 3% to 19% in one of the
earliest publications.7 The large variance in the incidence of thrombus formation
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Dmight reflect the results of different modifications of the
Fontan procedure, the various durations of postoperative
follow-up, and the diagnostic method used to identify in-
tracardiac thrombi in the majority of asymptomatic pa-
tients.5,6,8,9 Liver dysfunction or protein-losing enteropathy
may result in changes of synthesis of procoagulant and
anticoagulant factors, influencing the balance of the coagu-
lation and fibrinolytic system.3,10-12
The optimum type and duration of postoperative antico-
agulation therapy is still a matter of discussion because no
controlled studies comparing different strategies preventing
thromboembolic complications are available yet. Initial an-
ticoagulation with warfarin sodium (Coumadin) has been
recommended by some authors for all patients after Fontan-
type surgery irrespective of the individual situation.5,12,13
In this study we analyzed the initial intention to treat and
assessed the results of a long-term risk-stratified prophylac-
tic treatment depending on the potential predisposing cir-
cumstances in our patients after a total cavopulmonary
anastomosis.
Patients and Methods
This is a retrospective study on 142 surviving patients who under-
went a total cavopulmonary anastomosis between 1988 and 2002
performed by 1 surgeon at 2 institutions (Table 1). Ethical com-
mittee approval was obtained, and informed consent was given by
all patients and their parents.
A total cavopulmonary anastomosis was accomplished by a
lateral partial prosthetic tunnel procedure in 121 patients (includ-
ing 38 patients with tunnel fenestration). In 16 of these patients,
the lateral tunnel was created with only autologous tissue. An
TABLE 1. Patient data (n  142)
n (%)
Diagnosis
Tricuspid atresia 30 (21.1)
Double-inlet ventricle 30 (21.1)
Complex univentricular heart 82 (57.7)
Heterotaxy syndrome 14 (9.8)
Fontan procedure
Total cavopulmonary anastomosis 121 (85.2)
(with fenestration n  38)
(with autologous intra-atrial
tunnel n  16)
Extracardiac conduit 21 (14.7)
Age at Fontan procedure Mean SD(range)
Total 66.3 57.9 (6-393 mo 5)
Total cavopulmonary anastomosis 67.8 52.1 (7-393 mo)
Extracardiac conduit 49.5 3 9.7 (6-151 mo)
Follow-up Mean SD (range)
Total 91.1 43.9 (12-177 mo)
Total cavopulmonary anastomosis 91.8 34.1 (18-129 mo)
Extracardiac conduit 48.3 21.7 (12-81 mo)extracardiac conduit procedure was performed in 21 patients. A
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Glenn or Fontan procedure in all patients except one. The age at
operation varied from 6 to 393 months (mean 66.3  57.9
months). The early postoperative period was defined as the time
before discharge or the first 30 postoperative days. The duration of
follow-up was 91.1 43.9 months (range 12-177 months) with 46
patients (32.3%) followed up for more than 10 years. Data on
postoperative cardiac catheterization were available for 97 pa-
tients. Yearly outpatient follow-up examinations included trans-
thoracic echocardiography with a Hewlett-Packard (Palo Alto,
Calif) ultrasound system (2.5-5 MHz transducer). Transthoracic
echocardiography was followed by transesophageal evaluation in
patients with a clinical suspicion of thrombus formation, a ques-
tionable finding on transthoracic echocardiography, or an in-
creased level of D-dimer as a potential marker of fibrinolysis.
Transesophageal echocardiography was also performed routinely
before cardiac catheterization. Thrombus formation at the atrial,
ventricular, or vascular level was defined as an echogenic mass
adherent to cardiac structures and described with regard to local-
ization and size. Laboratory investigations were performed for
hereditary thrombophilia and coagulation factor analysis on a
cross-sectional basis including screening for prothrombotic state
with imbalance of procoagulation and anticoagulation factors and
liver dysfunction. Late dysrhythmia was defined as sinuatrial dys-
function or intra-atrial reentry tachycardia (IART) with the need
for antiarrhythmic medication.14 Protein-losing enteropathy was
diagnosed in patients with clinical symptoms related to hypopro-
teinemia; when indicated, the a1-antitrypsin clearance was calcu-
lated.15
The initial antithrombotic treatment was based on the surgical
method and influenced by preoperative parameters and early post-
operative functional result. It was modified during long-term fol-
low-up when thromboembolic complications occurred or sequelae
such as atrial tachydysrhythmia, symptomatic protein-losing en-
teropathy, polycythemia, or ventricular dysfunction associated
with systemic venous slow blood flow phenomenon on echocar-
diogram developed. This resulted in 22 cross-overs to warfarin
during follow-up.
After the early postoperative period, 85 patients with a partial
prosthetic venous pathway (including patients with tunnel fenes-
tration) were treated with acetylsalicylic acid (ASA; 3-5 mg/kg per
day). No anticoagulation was administered to 16 patients with
autologous tissue venous pathways and 29 patients with partial
prosthetic venous pathways and an uncomplicated early postoper-
ative period. Six patients received warfarin as initial treatment
because of borderline preoperative hemodynamic parameters or
related to surgical technique. Eight patients received heparin for
prolonged pleural effusions or immobilization and crossed over to
ASA or warfarin during follow-up (Figure 1).
Statistical Analysis
When appropriate, data were expressed as mean  standard
deviation. All data were analyzed using SPSS statistical
software (SPSS Inc, Chicago, Ill). Numeric data were ana-
lyzed with the unpaired t test; categorical data were ana-
lyzed with chi-square analysis.
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DResults
Incidence of Thrombus Formation and
Thromboembolic Events
A total of 142 survivors were assessed (none of the patients
who died during the early or late postoperative period died
of a thromboembolic event or thrombus formation). Throm-
bus formation and thromboembolic events occurred in 10
patients (7%). Eight of these patients (5.6%) presented with
systemic venous thrombus formation, whereas arterial em-
boli resulted in a stroke in 2 patients (1.4%) (Table 2). Six
of 8 patients with right-sided thrombi were asymptomatic; 2
patients (patients 1 and 5) had symptoms of supraventricular
tachycardia and venous congestion, respectively. In 3 addi-
tional patients (patients 6, 7, and 9), venous thrombus for-
mation was detected on the routine postoperative echocar-
diogram during the early postoperative period. Potential
predisposing factors were postoperative immobilization or a
central venous line. Late asymptomatic systemic venous
thrombi were detected in 3 patients (patients 2, 3, and 4);
symptomatic protein-losing enteropathy had already devel-
oped in 2 patients.
A stroke was the first symptom of a thromboembolic
complication in 2 patients (patients 8 and 10). This occurred
before discharge in the presence of prolonged postoperative
immobilization and protein-losing enteropathy in 1 patient.
The second patient was admitted 20 months after the Fon-
tan-type procedure with neurologic signs of a stroke; 6
weeks before, he had been placed on high molecular weight
heparin (5000 U/m2 bovine serum albumin subcutaneously)
for treatment of recurrent symptomatic protein-losing enter-
opathy. Altogether, 8 of 10 patients with thromboembolic
events received heparin (administered intravenously in 7
Figure 1. Antithpatients [maintenance dosage 15-25 U kg1 · h1] and
The Journal of Thoracisubcutaneously in 1 patient) at the time of thrombus forma-
tion, mainly for postoperative immobilization (Table 2), and
presented with a partial thromboplastin time of 50 to 60
seconds or more (except for patient 6). The Kaplan-Meier
estimate for freedom from a thrombotic or thromboembolic
event (systemic venous or arterial) is 91.6% at 5 years and
78.8% at 10 years (Figure 2).
Risk-Stratified Anticoagulant Prophylaxis During
Long-Term Follow-up
According to initial management, 45 patients (including 16
patients with autologous venous pathway) received no an-
ticoagulation. During long-term follow-up, 5 patients
crossed over to warfarin (Figure 1) because of complica-
tions or functional sequelae in 3 and a thromboembolic
event in 1. One patient crossed over to warfarin because of
a patent pulmonary valve with residual pulmonary artery
stump, as recommended in recent studies.16,17 None of the
remaining 40 patients had specific sequelae of the Fontan
circulation during long-term follow-up; so far, 38 patients
have undergone cardiac catheterization confirming an ade-
quate morphologic and hemodynamic result. A total of 85
patients were initially treated with ASA; 74 patients who
remained on long-term ASA medication (Figure 1) crossed
over to warfarin because of functional sequelae of the
Fontan circulation or a thromboembolic event. None of
these patients presented with clinical symptoms of throm-
boembolic events or suspicious findings on transthoracic
echocardiogram; 45 patients had undergone cardiac cathe-
terization combined with transesophageal echocardiography
to exclude any tunnel obstruction.
The number of patients who received warfarin increased
otic treatment.from 6 to 28 during follow-up. Cross-over to warfarin was
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DTABLE 2. Patients with thromboembolic events
Patient 1 Patient 2 Patient 3
Anatomy PA/IVS DORV, MGA, DILV, TGA, coarctation
Surgery TCPA TCPA TCPA
Age at operation 135 mo 57 mo 114 mo
Thrombus formation
Localization iT iT iT
Interval to surgery 12 d 108 mo 3 mo
Symptoms SVT — —
Prophylaxis of thrombus at diagnosis Heparin — Warfarin
Potential predisposing circumstances Anastomosis stenosis — Ventricular dysfunction, PLE
Thrombus therapy Reoperation (anastomosis revision) Warfarin rt-PA
Long-term prophylaxis ASA for the first postop year;
beginning warfarin 12 y postop
Warfarin Warfarin
Patient 4 Patient 5
Anatomy HLHS DORV, MGA
Surgery TCPA Fenestrated TCPA
Age at operation 27 mo 9 mo
Thrombus formation
Localization iT Fenestration
Interval to surgery 49 mo 3 d
Symptoms — Increased systemic venous
pressure
Prophylaxis of thrombus at diagnosis Heparin Heparin




Thrombus therapy Warfarin Reoperation (refenestration)
Long-term prophylaxis Warfarin ASA
Patient 6 Patient 7 Patient 8
Anatomy Heterotaxy syndrome,





Surgery TCPA Extracardiac CPC TCPA
Age at operation 132 mo 52 mo 68 mo
Thrombus formation
Localization iT SVC Not detected
Interval to surgery 25 d 6 d 2 mo
Symptoms — —
Cerebrovascular accident
Prophylaxis of thrombus at diagnosis Heparin Heparin Heparin
Potential predisposing circumstances Postop immobilization
(pleural drainage)
Central venous line Postop immobilization PLE
(cholelithiasis, drainage)
Thrombus therapy rt-PA Heparin Heparin
Long-term prophylaxis ASA, beginning
warfarin 3 y postop
ASA Warfarin
Patient 9 Patient 10
Anatomy DORV, TGA, SPS, PS TA IIc
Surgery TCPA Fenestrated TCPA
Age at operation 7 mo 20 mo
Thrombus formation
Localization iT Not detected
Interval to surgery 21 d 10 mo 
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Dinitiated because of a thromboembolic event in 7 patients or
the development of potential predisposing causes for throm-
boembolic complications (Table 3); prophylactic anticoag-
ulation was begun 16 to 110 months (mean 56.2  32.2
months) postoperatively. None of these patients had bleed-
ing complications. Patients without any antithrombotic pro-
phylaxis had significantly longer mean follow-up (123.8 
32.3 months) compared with patients who received warfarin
(101.4  46.6 months; P  .04) or ASA (69.7  34.8
months; P .005).
Atrial dysrhythmia defined as IART occurred in 18 pa-
tients (12.6%); 6 of these patients who required antiarrhyth-
mic medication received warfarin (Table 3). Evidence of
protein-losing enteropathy was found in 9 patients (6.3%).
Four of these patients had a history of thromboembolic
complications with or after the onset of symptoms of pro-
tein-losing enteropathy and were subsequently placed on
warfarin. Two additional patients had symptomatic protein-
losing enteropathy and received prophylactic anticoagula-
tion treatment 23 and 60 months postoperatively. Slow
blood flow phenomenon and ventricular dysfunction docu-
mented on echocardiographic follow-up studies led to pro-
TABLE 2. Continued
Symptoms
Prophylaxis of thrombus at diagnosis He
Potential predisposing circumstances Pos
Thrombus therapy Wa
Long-term prophylaxis AS
ASA, Acetylsalicylic acid; CAVSD, common atrioventricular septal defec
cavopulmonary connection; HLHS, hypoplastic left-heart syndrome; iT, i
atresia/intact ventricular septum; PAPVD, partial anomalous pulmonary ve
recombinant tissue-type plasminogen activator; SA, single atrium; SC, subc
cava; SVT, supraventricular tachycardia; TA, tricuspid atresia; TAPVD
anastomosis; TGA, transposition of the great arteries.
Figure 2. Kaplan-Meier estimate for freedom from thrombotic or
thromboembolic events.phylactic warfarin medication in 7 adolescent patients (aged
The Journal of Thoraci136-245 months) 40 to 110 months postoperatively. After
transcatheter procedures (closure of residual interatrial com-
munications/fenestrations in 11 patients and device closure
of a reopened left superior caval vein draining into the
coronary sinus in 3 patients), patients continued to receive
ASA, except for 3 patients who remained on warfarin (2
patients with a history of thromboembolic complication or
protein-losing enteropathy). None of these patients had a
late thromboembolic event during follow-up.
Discussion
The number of reports on thrombotic and thromboembolic
complications after the Fontan operation is increasing, re-
flecting longer postoperative survival and duration of fol-
low-up. Recent studies reported an incidence as high as 20%
for systemic venous and arterial thrombosis with an un-
known ratio of asymptomatic patients.4-6,18 Therefore, the
true incidence of cardiac thrombi is unknown.
Anticoagulation strategies have been considered with
various ideas concerning the indication and type and dura-
tion of therapy.8,13,16 Some of these suggestions, however,
were based on the experience of patients undergoing previ-
atient 9 Patient 10
— Cerebrovascular accident
Heparin SC (PLE)
immobilization PLE, fenestrated occclusion
for 3 mo Warfarin
Warfarin
V, double inlet left ventricle; DORV, double outlet right ventricle; CPC,
trial tunnel; MGA, malposition of the great arteries; PA/IVS, pulmonary
drainage; PLE, protein-losing enteropathy; PS, pulmonary stenosis; rt-PA,
ous; SPS, subpulmonary stenosis; SV, single ventricle; SVC, superior vena
l anomalous pulmonary venous drainage; TCPA, total cavopulmonary
TABLE 3. Special indications for anticoagulant treatment
with warfarin (25/142 patients)
Prior thrombus formation/thromboembolic event
(including 4 patients with PLE)
7
Tunnel-fenestration 2
Residual PA trunk 1
Atrial dysrhythmia/IART 6
Slow blood flow phenomenon on TTE 3
Ventricular dysfunction 4
Polycythemia 3
Venous congestion/elevated PA pressure 1
After transcatheter intervention (fenestration
closure)
1
IART, Intra-atrial reentry tachycardia; PA, pulmonary artery; PLE, protein-









, totaous types of univentricular palliation. These included a high
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total cavopulmonary anastomosis and a blind pouch left
after main pulmonary artery ligation/division. Because of a
high incidence of late thromboembolic complications in
these patients, long-term anticoagulant therapy with warfa-
rin was recommended for all patients undergoing a Fontan
procedure irrespective of the surgical technique or addi-
tional predisposing factors.9,13 On the basis of the assump-
tion that potential risk factors may exist and can be used as
a rationale to decide on different anticoagulation treatment
regimens, we assessed the relationship between individual-
ized treatment and outcome, that is, thromboembolic prob-
lems in patients after total cavopulmonary anastomosis. Our
results show that the surgical technique is relevant in 2
aspects. None of the 16 patients with an autologous tunnel
procedure had thrombus formation, although they did not
receive any anticoagulation medication as part of our strat-
egy. This may be related to the nonturbulent systemic ve-
nous flow dynamics with the preservation of a somewhat
pulsatile flow by atrial contraction and less respiratory-
dependent venous return.19 Thrombus formation in the re-
sidual pulmonary trunk after pulmonary artery ligation or
division with the risk of arterial embolization and cerebral
infarction is not a rare event; it has been described in
approximately 30% to 50% of patients with thrombus for-
mation after univentricular palliation.9,18 However, it was
our policy to start to close any pulmonary trunk at the
pulmonary valve annulus level. We succeeded in all but 1
patient, who was then administered anticoagulation treat-
ment. Because of the potentially serious sequelae, diagnosis
of a thrombus in the pulmonary stump should prompt urgent
removal and closure of the pulmonary valve even in asymp-
tomatic patients.16
As reported in the literature, the type of material used for
creation of the lateral tunnel or the presence of fenestrations
did not affect the risk of stroke.7,17,18 After tunnel fenestra-
tion, a high proportion of spontaneous fenestration closures
during follow-up has been described, limiting the potential
risk of paradoxic thromboembolism.20 In our study, patients
with persistent tunnel fenestration were placed on ASA
(except for 2 patients), although an increased risk of stroke
has not been proven in these patients.7
Early experience in patients who underwent an extracar-
diac conduit procedure revealed a high incidence of throm-
bus formation,5,21 but the number of patients under ex-
tended follow-up is still limited. None of the young patients
who had recently undergone an extracardiac conduit proce-
dure at our institution were placed on warfarin. However,
we never used prosthetic tubes in the extracardiac Fontan
procedure; we used as much autologous tissue (mainly in
situ pericardium) as possible.
All patients with a history of thrombus formation in our
study had at least 1 potential predisposing factor that might
574 The Journal of Thoracic and Cardiovascular Surgery ● Marincrease the risk of thromboembolic complications. The
findings of other investigators4,7,22 (ie, supraventricular
tachycardia and IART may promote thrombus formation on
an atrial level) prompted us to anticoagulate our patients
with recurrent atrial tachydysrhythmia. Thrombus forma-
tion in association with the diagnosis of protein-losing en-
teropathy occurred in 4 of our 10 patients. This clinical
observation had not been made in the literature. The poten-
tial risk of imbalance of the procoagulant and anticoagulant
factors in patients with protein-losing enteropathy, resulting
from similar molecular weights for albumin, protein C and
S, antithrombin III, and factors II and X, had already been
described by Cromme-Dijkhuis and associates.10 Patients
with protein-losing enteropathy and thrombus formation in
our study did not show a uniform pattern of coagulation
factor abnormalities. Under therapy with warfarin, none of
these patients experienced further thrombosis during fol-
low-up.
The follow-up in our patients was too short and the
number of patients was too small to confirm the impression
of other studies that the incidence of arrhythmias and throm-
boembolic events increases with the duration of follow-up,
especially after 10 years.2,13 On the other hand, patients
with long-term follow-up and adult patients are at risk for
systemic ventricular dysfunction; in this case, we believe
that anticoagulation treatment is indicated especially when
contrast echocardiograms demonstrate a slow blood flow
situation, which is probably caused by spontaneous micro-
cavitations within the cavopulmonary connection.23 One
major potential predisposing factor in our study was pro-
longed postoperative immobilization documented in 4 pa-
tients with thrombus formation. Postoperative hepariniza-
tion was routinely started in all patients shortly after the
Fontan procedure or noncardiac surgery (with prolongation
of partial thromboplastin time to 50-60 seconds), as recom-
mended in adults and adapted for children.6 However, dis-
ease states might coexist that influence plasma concentra-
tions of antithrombin or the anticoagulant capacity of
heparin by an increase in acute phase proteins.6,8 Coagula-
tion factor abnormalities potentially predisposing to throm-
boembolic events have been described in recent reports in
various constellations after the Fontan procedure, suggest-
ing an unpredictable risk of imbalance in procoagulant and
anticoagulant factors with the need for anticoagulation treat-
ment.24,25 However, there is presently no coagulation profile
that can be used to identify patients at increased risk for
thrombus formation or permanent abnormal consumption of
coagulation factors.
Limitations of the Study
Transesophageal echocardiography has proven to be the
method of choice to identify intracardiac thrombi in the
majority of asymptomatic patients, especially older children
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Dand young adults.5,9,23 Because transesophageal echocardi-
ography was not performed on a routine basis in all of our
patients, the true incidence of asymptomatic cardiac
thrombi may have been underestimated.
The relatively small number of patients with a thrombo-
embolic event during follow-up limits the possibility of
identifying a risk factor with statistical significance.
Conclusion
In all of our patients, thrombus formation was associated
with at least 1 additional potential predisposing factor, such
as postoperative prolonged immobilization, protein-losing
enteropathy, stenosis of the cavopulmonary anastomosis, or
atrial arrhythmia, and seems to be highest in the first year
after a total cavopulmonary anastomosis. Primary surgery
with consequent closure of a patent pulmonary valve,
thereby avoiding thrombogenic “blind” pulmonary artery
stump, contributed to the low incidence of late thromboem-
bolic events in our cohort. Because our prophylactic anti-
coagulation strategy proved effective in the prevention of
thrombotic complications during long-term follow-up, we
do not believe that initial anticoagulation therapy is rou-
tinely required in all young children after a total cavopul-
monary anastomosis.
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